Singh Akanksha, Singh Ankur, Mishra Om Prakash, Prasad Rajniti, Narayan Gopeshwar, Batra Vineeta V, Tabatabaeifar Mansoureh, Schaefer Franz
Division of Pediatric Nephrology, Department of Pediatrics, Institute of Medical Sciences, Varanasi, Uttar Pradesh, India.
Department of Molecular and Human Genetics, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
J Pediatr Genet. 2021 Feb 9;11(3):185-191. doi: 10.1055/s-0040-1722286. eCollection 2022 Sep.
Steroid-resistant nephrotic syndrome (SRNS) patients with genetic mutations most commonly have histology of focal segmental glomerulosclerosis (FSGS) and do not respond to immunosuppressive drugs. We report the molecular screening results of 18 pediatric SRNS cases presented to our nephrology clinic. Three pathogenic variants have been detected, two previously reported and one novel variant. The reported pathogenic variants have been detected in and genes. A novel pathogenic variant has been detected in the inverted formin 2 gene ( ) gene. We did not detect any variant of the gene. There were 13 males. Mean age of study participants at enrollment was 69 months. There were 12 cases of primary SRNS. The mean duration from onset of symptoms to SRNS diagnosis was 13 months. FSGS and minimal change disease (MCD) were present in the same number of cases. The response rate (complete or partial) to immunosuppressive drugs was seen in only one patient in the genetic SRNS group ( = 3), while the response rate in nongenetic cases ( = 15) was 80%. Two nonresponders in the genetic SRNS group had FSGS for histopathology and pathogenic variants (NPHS2 and INF2). The other three nonresponders in the nongenetic SRNS group had both FSGS ( = 1) and MCD ( = 2) histopathology. There were two deaths in the study cohort of the nongenetic SRNS group. This study highlights the screening of the SRNS cohort by a panel of extended genes rather focussing on the three most common genes ( , , and ). This further confirms the molecular etiology of SRNS in three cases and extends the list of pathogenic variants of genetic SRNS in the North Indian population. This is the first study in the eastern part of Uttar Pradesh in India.
患有基因突变的类固醇抵抗性肾病综合征(SRNS)患者最常见的组织学表现为局灶节段性肾小球硬化(FSGS),且对免疫抑制药物无反应。我们报告了在我们肾脏病诊所就诊的18例儿科SRNS病例的分子筛查结果。已检测到三个致病变异,两个是先前报道过的,一个是新变异。已在 和 基因中检测到报道的致病变异。在倒转formin 2基因( )基因中检测到一个新的致病变异。我们未检测到 基因的任何变异。有13名男性。研究参与者入组时的平均年龄为69个月。有12例原发性SRNS。从症状出现到SRNS诊断的平均持续时间为13个月。FSGS和微小病变病(MCD)的病例数相同。基因性SRNS组( = 3)中只有一名患者对免疫抑制药物有反应(完全或部分反应),而非基因性病例( = 15)的反应率为80%。基因性SRNS组中的两名无反应者组织病理学为FSGS且有致病变异(NPHS2和INF2)。非基因性SRNS组中的其他三名无反应者组织病理学既有FSGS( = 1)又有MCD( = 2)。非基因性SRNS组的研究队列中有两例死亡。本研究强调了通过一组扩展基因对SRNS队列进行筛查,而不是仅关注三个最常见的基因( 、 和 )。这进一步证实了三例SRNS的分子病因,并扩展了北印度人群中基因性SRNS的致病变异列表。这是印度北方邦东部的第一项研究。